<p>股东们可能注意到，<strong>石药集团</strong>（HKG:1093）在上周这个时候发布了季度业绩。初步反应并不积极，过去一周股价下跌了 2.5%，至 7.50 港元。综合来看，这似乎是一个相当糟糕的结果。尽管收入为 66 亿人民币符合分析师的预测，但法定收益大幅低于预期，未能达到预估，只有每股 0.077 人民币，低于预期 33%。收益对投资者来说是一个重要的时刻，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。我们认为读者会发现分析师最新的（法定）收益后预测很有趣。</p>
<p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/879722-earnings-and-revenue-growth-1-dark-2/1780102596062?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/879722-earnings-and-revenue-growth-1-dark-2/1780102596062"/></p>
<p>SEHK:1093 收益和收入增长 2026 年 5 月 30 日</p>
<p>考虑到最新的业绩，来自 20 位分析师对石药集团的最新共识是，2026 年的收入为 315 亿人民币。如果实现，这将意味着过去 12 个月收入的重大增长，达到 24%。每股收益预计将飙升 154%，达到 0.72 人民币。在这份报告发布之前，分析师们曾预测 2026 年的收入为 300 亿人民币，每股收益（EPS）为 0.58 人民币。情绪有明显的提升，分析师们上调了收入预期，并对每股收益进行了显著提升。</p>
<p>查看我们对石药集团的最新分析</p>
<p>尽管有这些上调，分析师们并没有对其目标价 11.46 港元做出重大改变，这表明更高的预估不太可能对股票的长期价值产生影响。不过，还有另一种看待目标价的方法，那就是查看分析师提出的目标价范围，因为广泛的估计范围可能表明对企业可能结果的不同看法。对石药集团的看法存在一些差异，最乐观的分析师将其估值为 19.36 港元，而最悲观的分析师则为每股 6.00 港元。可以看出，估计范围很广，最低估值不到最乐观估值的一半，这表明分析师对该企业的表现有着强烈的分歧看法。考虑到这一点，我们不应过于依赖共识目标价，因为这只是一个平均值，分析师显然对该企业有着深刻的分歧看法。</p>
<p>现在从更大的视角来看，我们可以通过将这些预测与过去的表现和行业增长预期进行比较来理解这些预测。这些估计中有一点突出，即石药集团预计未来的增长速度将快于过去，预计到 2026 年收入将显示出 33% 的年化增长。如果实现，这将比过去五年的 0.5% 的年均下降要好得多。与分析师对更广泛行业的估计相比，后者预计（总体上）行业收入将年均增长 11%。不仅石药集团的收入预计将改善，分析师们似乎也预计其增长速度将快于更广泛的行业。</p>
<h2>结论</h2>
<p>我们最大的收获是共识每股收益的上调，这表明对石药集团明年收益潜力的情绪明显改善。令人高兴的是，他们还上调了收入预期，并预计其增长速度将快于更广泛的行业。共识目标价保持在 11.46 港元，最新的估计不足以对其目标价产生影响。</p>
<p>考虑到这一点，我们仍然认为企业的长期发展轨迹对投资者来说更为重要。我们有来自多位石药集团分析师的估计，直到 2028 年，你可以在我们的平台上免费查看。</p>
<p>即便如此，请注意，石药集团在我们的投资分析中显示出 <strong>1 个警告信号</strong>，你应该知道...</p>
<h3><strong>新：AI 股票筛选器和警报</strong></h3>
<p>我们的新 AI 股票筛选器每天扫描市场，发现机会。</p>
<p>• 分红强劲（收益率 3%+）</p>
<p>• 内部人士买入的被低估小盘股</p>
<p>• 高增长科技和 AI 公司</p>
<p>或者从 50 多个指标中构建自己的筛选器。</p>
<p>立即免费探索</p>

石药集团

广发中证香港创新药(QDII-ETF)

华泰柏瑞恒生创新药ETF(QDII)

<p>石药集团第一季度的盈利未能达到预期，差距达到 33%，导致股价下跌 2.5%。然而，分析师已上调了 2026 年的预测，预计收入将增长 24%，达到 315 亿人民币，每股收益将激增 154%，达到 0.72 人民币。尽管这些积极的情绪变化和对比行业更快增长的预期，市场共识目标价仍保持在 11.46 港元，反映出分析师观点的分歧</p>

<p>Shareholders might have noticed that <strong>CSPC Pharmaceutical Group Limited</strong> (HKG:1093) filed its quarterly result this time last week. The early response was not positive, with shares down 2.5% to HK$7.50 in the past week. It looks like a pretty bad result, all things considered. Although revenues of CN¥6.6b were in line with analyst predictions, statutory earnings fell badly short, missing estimates by 33% to hit CN¥0.077 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.</p>
<div class="lb-trans"><p>股东们可能注意到，<strong>石药集团</strong>（HKG:1093）在上周这个时候发布了季度业绩。初步反应并不积极，过去一周股价下跌了 2.5%，至 7.50 港元。综合来看，这似乎是一个相当糟糕的结果。尽管收入为 66 亿人民币符合分析师的预测，但法定收益大幅低于预期，未能达到预估，只有每股 0.077 人民币，低于预期 33%。收益对投资者来说是一个重要的时刻，因为他们可以跟踪公司的表现，查看分析师对明年的预测，并观察对公司的情绪是否发生变化。我们认为读者会发现分析师最新的（法定）收益后预测很有趣。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/879722-earnings-and-revenue-growth-1-dark-2/1780102596062" alt="" original-src="https://images.simplywall.st/asset/chart/879722-earnings-and-revenue-growth-1-dark-2/1780102596062"/></p>
<p>SEHK:1093 Earnings and Revenue Growth May 30th 2026</p>
<div class="lb-trans"><p>SEHK:1093 收益和收入增长 2026 年 5 月 30 日</p>
</div><p>Taking into account the latest results, the most recent consensus for CSPC Pharmaceutical Group from 20 analysts is for revenues of CN¥31.5b in 2026. If met, it would imply a major 24% increase on its revenue over the past 12 months. Per-share earnings are expected to shoot up 154% to CN¥0.72. In the lead-up to this report, the analysts had been modelling revenues of CN¥30.0b and earnings per share (EPS) of CN¥0.58 in 2026. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a considerable lift to earnings per share in particular.</p>
<div class="lb-trans"><p>考虑到最新的业绩，来自 20 位分析师对石药集团的最新共识是，2026 年的收入为 315 亿人民币。如果实现，这将意味着过去 12 个月收入的重大增长，达到 24%。每股收益预计将飙升 154%，达到 0.72 人民币。在这份报告发布之前，分析师们曾预测 2026 年的收入为 300 亿人民币，每股收益（EPS）为 0.58 人民币。情绪有明显的提升，分析师们上调了收入预期，并对每股收益进行了显著提升。</p>
</div><p>View our latest analysis for CSPC Pharmaceutical Group</p>
<div class="lb-trans"><p>查看我们对石药集团的最新分析</p>
</div><p>Despite these upgrades,the analysts have not made any major changes to their price target of HK$11.46, suggesting that the higher estimates are not likely to have a long term impact on what the stock is worth. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on CSPC Pharmaceutical Group, with the most bullish analyst valuing it at HK$19.36 and the most bearish at HK$6.00 per share. As you can see the range of estimates is wide, with the lowest valuation coming in at less than half the most bullish estimate, suggesting there are some strongly diverging views on how analysts think this business will perform. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.</p>
<div class="lb-trans"><p>尽管有这些上调，分析师们并没有对其目标价 11.46 港元做出重大改变，这表明更高的预估不太可能对股票的长期价值产生影响。不过，还有另一种看待目标价的方法，那就是查看分析师提出的目标价范围，因为广泛的估计范围可能表明对企业可能结果的不同看法。对石药集团的看法存在一些差异，最乐观的分析师将其估值为 19.36 港元，而最悲观的分析师则为每股 6.00 港元。可以看出，估计范围很广，最低估值不到最乐观估值的一半，这表明分析师对该企业的表现有着强烈的分歧看法。考虑到这一点，我们不应过于依赖共识目标价，因为这只是一个平均值，分析师显然对该企业有着深刻的分歧看法。</p>
</div><p>Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that CSPC Pharmaceutical Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 33% annualised growth until the end of 2026. If achieved, this would be a much better result than the 0.5% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 11% annually. Not only are CSPC Pharmaceutical Group's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.</p>
<div class="lb-trans"><p>现在从更大的视角来看，我们可以通过将这些预测与过去的表现和行业增长预期进行比较来理解这些预测。这些估计中有一点突出，即石药集团预计未来的增长速度将快于过去，预计到 2026 年收入将显示出 33% 的年化增长。如果实现，这将比过去五年的 0.5% 的年均下降要好得多。与分析师对更广泛行业的估计相比，后者预计（总体上）行业收入将年均增长 11%。不仅石药集团的收入预计将改善，分析师们似乎也预计其增长速度将快于更广泛的行业。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around CSPC Pharmaceutical Group's earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at HK$11.46, with the latest estimates not enough to have an impact on their price targets.</p>
<div class="lb-trans"><p>我们最大的收获是共识每股收益的上调，这表明对石药集团明年收益潜力的情绪明显改善。令人高兴的是，他们还上调了收入预期，并预计其增长速度将快于更广泛的行业。共识目标价保持在 11.46 港元，最新的估计不足以对其目标价产生影响。</p>
</div><p>Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple CSPC Pharmaceutical Group analysts - going out to 2028, and you can see them free on our platform here.</p>
<div class="lb-trans"><p>考虑到这一点，我们仍然认为企业的长期发展轨迹对投资者来说更为重要。我们有来自多位石药集团分析师的估计，直到 2028 年，你可以在我们的平台上免费查看。</p>
</div><p>Even so, be aware that CSPC Pharmaceutical Group is showing <strong>1 warning sign in our investment analysis</strong> , you should know about...</p>
<div class="lb-trans"><p>即便如此，请注意，石药集团在我们的投资分析中显示出 <strong>1 个警告信号</strong>，你应该知道...</p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：AI 股票筛选器和警报</strong></h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新 AI 股票筛选器每天扫描市场，发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲（收益率 3%+）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士买入的被低估小盘股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长科技和 AI 公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

CSPC Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Simplywall

汇添富国证港股通创新药ETF

生物科技ETF基金

富国恒生港股通创新药及医疗保健ETF

博时恒生港股通创新药精选ETF

易方达中证生物科技主题ETF

招商中证生物科技主题ETF

易方达沪深300医药ETF

香港医药

华夏上证科创板生物医药ETF

博时恒生医疗保健(QDII-ETF)

国泰中证生物医药ETF

华夏中证生物科技主题ETF

华夏医药ETF

创新药

华夏恒生生物科技ETF(QDII)

华宝中证制药ETF

易方达恒生港股通创新药ETF

华宝恒生港股通创新药精选ETF

石药集团有限公司的收益未达分析师预期：以下是分析师的最新预测